Markers potentially associated with CR to corticosteroids and steroid-refractory GI-GVHD (univariate analysis)
| Markers . | N . | Cumulative incidence of CR, % (95% CI) . | P . | Probability for SR-GVHD (%) . | P . |
|---|---|---|---|---|---|
| Calprotectin | |||||
| < 100 μg/g | 35 | 86 (68-94) | 12 (34) | ||
| ≥ 100 μg/g | 16 | 56 (24-79) | .05 | 15 (94) | < .0001 |
| Elastase | |||||
| > 200 μg/g | 29 | 86 (65-95) | 14 (48) | ||
| ≤ 200 μg/g | 22 | 64 (38-81) | .12 | 13 (59) | .57 |
| α1-antitrypsin | |||||
| < 1.5 mg/g | 21 | 90 (59-98) | 5 (24) | ||
| ≥ 1.5 mg/g | 30 | 67 (46-81) | .0007 | 22 (73) | .0007 |
| Apoptosis | |||||
| Absent | 8 | 62 (17-88) | 8 (100) | ||
| Present | 24 | 83 (59-94) | .20 | 9 (38) | .003 |
| Vascular damage | |||||
| Absent | 28 | 86 (63-95) | 13 (46) | ||
| Present | 4 | 25 (0-73) | .084 | 4 (100) | .10 |
| Abrasions | |||||
| Absent | 21 | 90 (61-98) | 8 (38) | ||
| Present | 11 | 55 (20-80) | .16 | 9 (82) | .028 |
| Albumin | |||||
| > 30 g/L | 24 | 87 (63-96) | 7 (29) | ||
| ≤ 30 g/L | 23 | 61 (35-79) | .006 | 19 (83) | .0004 |
| GI-GVHD stage | |||||
| 1 | 23 | 87 (61-96) | 7 (30) | ||
| 2 | 14 | 79 (40-94) | 8 (57) | .004 | |
| 3 | 14 | 57 (26-79) | .15 | 12 (86) | |
| WHO PS | |||||
| 1-2 | 36 | 86 (68-94) | 15 (42) | ||
| 3-4 | 15 | 53 (20-78) | .028 | 12 (80) | .016 |
| Markers . | N . | Cumulative incidence of CR, % (95% CI) . | P . | Probability for SR-GVHD (%) . | P . |
|---|---|---|---|---|---|
| Calprotectin | |||||
| < 100 μg/g | 35 | 86 (68-94) | 12 (34) | ||
| ≥ 100 μg/g | 16 | 56 (24-79) | .05 | 15 (94) | < .0001 |
| Elastase | |||||
| > 200 μg/g | 29 | 86 (65-95) | 14 (48) | ||
| ≤ 200 μg/g | 22 | 64 (38-81) | .12 | 13 (59) | .57 |
| α1-antitrypsin | |||||
| < 1.5 mg/g | 21 | 90 (59-98) | 5 (24) | ||
| ≥ 1.5 mg/g | 30 | 67 (46-81) | .0007 | 22 (73) | .0007 |
| Apoptosis | |||||
| Absent | 8 | 62 (17-88) | 8 (100) | ||
| Present | 24 | 83 (59-94) | .20 | 9 (38) | .003 |
| Vascular damage | |||||
| Absent | 28 | 86 (63-95) | 13 (46) | ||
| Present | 4 | 25 (0-73) | .084 | 4 (100) | .10 |
| Abrasions | |||||
| Absent | 21 | 90 (61-98) | 8 (38) | ||
| Present | 11 | 55 (20-80) | .16 | 9 (82) | .028 |
| Albumin | |||||
| > 30 g/L | 24 | 87 (63-96) | 7 (29) | ||
| ≤ 30 g/L | 23 | 61 (35-79) | .006 | 19 (83) | .0004 |
| GI-GVHD stage | |||||
| 1 | 23 | 87 (61-96) | 7 (30) | ||
| 2 | 14 | 79 (40-94) | 8 (57) | .004 | |
| 3 | 14 | 57 (26-79) | .15 | 12 (86) | |
| WHO PS | |||||
| 1-2 | 36 | 86 (68-94) | 15 (42) | ||
| 3-4 | 15 | 53 (20-78) | .028 | 12 (80) | .016 |
GI indicates gastrointestinal; CR, complete response; CI, confidence interval; SR, steroid resistant; N, number of evaluated patients; and PS, performance status.